[go: up one dir, main page]

CN119192324A - Tyr-Pro-type casein peptide with sleep-improving activity and preparation method and application thereof - Google Patents

Tyr-Pro-type casein peptide with sleep-improving activity and preparation method and application thereof Download PDF

Info

Publication number
CN119192324A
CN119192324A CN202411386363.3A CN202411386363A CN119192324A CN 119192324 A CN119192324 A CN 119192324A CN 202411386363 A CN202411386363 A CN 202411386363A CN 119192324 A CN119192324 A CN 119192324A
Authority
CN
China
Prior art keywords
tyr
pro
casein
sleep
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411386363.3A
Other languages
Chinese (zh)
Inventor
赵谋明
钱兢菁
郑淋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China University of Technology SCUT
Original Assignee
South China University of Technology SCUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China University of Technology SCUT filed Critical South China University of Technology SCUT
Priority to CN202411386363.3A priority Critical patent/CN119192324A/en
Publication of CN119192324A publication Critical patent/CN119192324A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732Casein
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开一系列具有改善睡眠活性的Tyr‑Pro‑型酪蛋白肽及其制备方法与应用,所述酪蛋白改善睡眠肽,优选地是指包含Tyr‑Pro‑结构的5~7肽。具体序列为Tyr‑Pro‑Ser‑Tyr‑Gly,Tyr‑Pro‑Ser‑Gly‑Ala,Tyr‑Pro‑Phe‑Pro‑Gly,Tyr‑Pro‑Glu‑Leu‑Phe,Tyr‑Pro‑Ser‑Tyr‑Gly‑Leu‑Asn,Tyr‑Pro‑Ser‑Gly‑Ala‑Trp‑Tyr。本发明的酪蛋白Tyr‑Pro‑型5~7肽比其他酪蛋白Tyr‑型肽或其他长度的Tyr‑Pro‑型肽表现出更强的改善睡眠活性,在戊巴比妥钠诱导小鼠睡眠行为学中,可显著延长小鼠睡眠时间达到2526.28±220.32s~3539.65±835.41s,其睡眠时间可达阳性对照组的57.57%~78.24%,可应用于改善睡眠的功能性食品或药物中。

The present invention discloses a series of Tyr-Pro-type casein peptides with sleep-improving activity, and preparation methods and applications thereof. The casein sleep-improving peptides preferably refer to 5-7 peptides containing a Tyr-Pro-structure. The specific sequences are Tyr-Pro-Ser-Tyr-Gly, Tyr-Pro-Ser-Gly-Ala, Tyr-Pro-Phe-Pro-Gly, Tyr-Pro-Glu-Leu-Phe, Tyr-Pro-Ser-Tyr-Gly-Leu-Asn, Tyr-Pro-Ser-Gly-Ala-Trp-Tyr. The casein Tyr-Pro-type 5-7 peptides of the present invention show stronger sleep-improving activity than other casein Tyr-type peptides or Tyr-Pro-type peptides of other lengths. In the sleep behavior of mice induced by sodium pentobarbital, the sleep time of mice can be significantly prolonged to 2526.28±220.32s~3539.65±835.41s, and the sleep time can reach 57.57%~78.24% of the positive control group. The peptides can be applied to functional foods or drugs for improving sleep.

Description

Tyr-Pro-casein peptide with sleep improving activity, and preparation method and application thereof
Technical Field
The invention relates to bioactive peptides for improving anxiety sleep disorder, in particular to a series of Tyr-Pro-type casein peptides with sleep improving activity, and a preparation method and application thereof.
Background
Insomnia refers to a series of phenomena such as difficulty in falling asleep, short sleep time, dreaminess, easy awakening, and the like, affects more than 35% of population worldwide, and is an important risk factor for causing mood disorder, fatigue, memory disorder, neuroinflammation, brain dysfunction and immunity decline.
Currently, sleep assessment can be divided into two main categories, objective sleep assessment and subjective sleep assessment methods. Because the mechanism or the target point of sleep disorder is complex, the sleeping disorder relates to a plurality of target points such as benzodiazepine receptors, 5-hydroxytryptamine, melatonin receptors and the like. Thus, there is currently no simple in vitro evaluation criteria that can represent a comprehensive sleep architecture. Sleep time is the most critical index for in vivo evaluation of insomnia and improvement of sleep activity by bioactive substances, and is usually measured by adopting a pentobarbital-induced mice sleep behavior test experiment. Therefore, the sleep improving effect of the active substance can be intuitively reflected by remarkably prolonging the sleep time of the pentobarbital sodium-induced mice.
Casein is an animal protein rich in Pro and Tyr, and has wide sources, rich resources and high nutritive value, and has great advantages for the development of bioactive products. Although different casein enzymatic products have been shown to have different sleep improving effects, the identification of sleep improving peptides is still limited. Representative alpha s 1-casein zymolyte prepared by trypsin shows sleep improving effect in a pentobarbital sodium-induced mouse sleep experiment, and a sleep improving peptide YLGYLEQLLR is obtained through separation and identification. In addition, casein obtained by enzymolysis with other specific commercial proteases has stronger effect on improving sleep enzymolysis products (patent CN114181292B and CN 112056453B). However, casein hydrolysates obtained with different proteases show different sleep improving effects, the underlying reasons of which are not clear. Further studies are needed to elucidate the detailed structural features of peptides from casein that are effective in improving sleep.
Therefore, by analyzing the structural characteristics of casein peptide, the method is helpful to develop more natural and safe sleep improving peptides. However, due to the limited data of the current sleep improving peptides, the prior art is still insufficient for the study of the structural features of the sleep improving peptides. Chinese patent (CN 112056453B) discloses an aromatic amino acid-rich sleep-improving zymolyte, and the casein zymolyte has a strong sleep-improving effect. However, how to improve the sleep improving effect of casein peptides rich in aromatic amino acids is not known, and the sequence characteristics of the existing sleep improving peptides are not reported sufficiently.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a series of Tyr-Pro-type casein peptides with strong sleep improving activity, and a preparation method and application thereof.
The Tyr-Pro-type casein peptide with the sleep improving activity is any one of Tyr-Pro,Tyr-Pro-Phe-Pro-Gly(SEQ.ID.NO.1),Tyr-Pro-Glu-Leu-Phe(SEQ.ID.NO.2),Tyr-Pro-Ser-Tyr-Gly-Leu-Asn(SEQ.ID.NO.3),,Tyr-Pro-Ser-Gly-Ala(SEQ.ID.NO.4),Tyr-Pro-Ser-Tyr-Gly(SEQ.ID.NO.5),Tyr-Pro-Ser-Gly-Ala-Trp-Tyr(SEQ.ID.NO.6),Tyr-Pro-Ser in sequence, and the Tyr-Pro-type casein peptide with the sleep improving activity is applied to preparation of functional foods or medicines for improving anxiety-type sleep disorder.
Further, the functional food is powder electuary, functional beverage, tabletting candy, gel soft candy or oral liquid, and the medicine is powder, tablet, liquid or capsule.
Furthermore, the functional food or the medicine also contains active ingredients and/or acceptable auxiliary materials which are used for improving sleep and are besides the Tyr-Pro-type casein peptide.
Further, the acceptable auxiliary materials in the functional food are milk powder, spina date seed, gamma-aminobutyric acid, whey protein peptide, collagen peptide, soybean peptide or melatonin, and the acceptable auxiliary materials in the medicine are sustained release agents, excipients, fillers, adhesives, wetting agents, disintegrating agents, absorption promoters, adsorption carriers, surfactants or lubricants.
Furthermore, the Tyr-Pro-type casein peptide with the sleep improving activity is a Tyr-Pro-based casein peptide with 5-7 amino acids extended from the C terminal, namely SEQ ID No. 4-6.
The invention provides a series of Tyr-Pro-type casein peptides with sleep improving activity, the amino acid sequence of the Tyr-Pro-type casein peptides with sleep improving activity is Tyr-Pro-Ser-Gly-Ala(SEQ.ID.NO.4),Tyr-Pro-Ser-Tyr-Gly(SEQ.ID.NO.5),Tyr-Pro-Ser-Gly-Ala-Trp-Tyr(SEQ.ID.NO.6),Tyr-Pro-Ser.
The preparation method for preparing the Tyr-Pro-type casein peptide with the sleep improving activity comprises the following steps:
(1) Adding casein and water, stirring and dissolving, and adjusting the pH to 6-8 to prepare casein dispersion;
(2) Adding serine proteinase and mixed proteinase M into the casein dispersion liquid in the step (1), carrying out synergistic enzymolysis, inactivating enzyme, and cooling;
(3) Centrifuging at 8000-10000 rpm and 4-10 ℃ for 10-20 min, and taking supernatant to obtain casein small molecule peptide solution containing SEQ ID No. 4-6 peptide fragments.
In the step (2), the serine protease is one of chymotrypsin and trypsin, the mixed protease M specifically comprises aminopeptidase and carboxypeptidase (preferably comprising 3:1 by mass ratio), the temperature of the synergistic enzymolysis is 35-55 ℃, and the time of the synergistic enzymolysis is 1-8h.
Further, the total protease addition amount of the serine protease and the mixed protease M in the step (2) is 0.2% -2.0% of the mass of casein, the mass ratio of the serine protease to the mixed protease M is (1-10): 10-19%, and the enzyme deactivation in the step (2) is to heat the enzymolysis liquid to 90-100 ℃ and boil for 15-30 min.
The casein enzymolysis product prepared by the preparation method, namely the casein small molecule peptide solution containing the peptide fragments of SEQ.ID.NO. 4-6, can prolong the sleep time by more than 2.37 times in the application of preparing the medicine and the health care product for improving the sleep.
The Tyr-Pro-type casein peptide and the enzymolysis product containing the Tyr-Pro-type casein peptide can obviously prolong the sleep time of a mouse induced by sodium pentobarbital, thereby showing stronger sleep improving activity. At the same time, sleep improvement is longer compared to other Tyr-type or different length Tyr-Pro-type peptides.
According to the Tyr-Pro-type casein peptide, the optimized Tyr-Pro-type 5-7 peptide intuitively reflects the sleep improving effect by prolonging the time effect of the pentobarbital sodium-induced mice. As reported in the prior art, the casein nonapeptide YPFGPPN (patent CN 117659154A) prolongs the time of inducing mice by pentobarbital sodium to 3186.83 +/-635.34 s, and compared with a positive pharmaceutical group, the sleeping activity is improved to 53.75%, and the casein Tyr-Pro-type 5-7 peptide can reach 57.57% -78.24%, so that the efficacy is remarkably improved.
In summary, proper addition of amino acids at the C-terminus of Tyr-Pro-monomers is an effective method for developing Tyr-type peptides with enhanced sleep activity, but is not necessarily more effective when extended, where a sequence length of 5-7 amino acids is more appropriate. Based on this, the Tyr-Pro-type casein peptide of the invention can be used for preparing functional foods or medicines with sleep improving effect.
Compared with the prior art, the invention has the following advantages and effects:
Compared with other Tyr-type peptides or Tyr-Pro-type peptides with other lengths, the Tyr-Pro-type 5-7 casein peptide provided by the invention has stronger sleep improving activity, remarkably prolongs the sleep time of mice induced by sodium pentobarbital, and can be applied to preparation of functional foods or medicines for improving sleep effectively.
Drawings
FIG. 1 is a graph showing the effect of Tyr-Pro-type 5-7 peptides, other Tyr-type peptides, and other lengths of Tyr-Pro-type peptides on sodium pentobarbital-induced sleep time in mice.
FIG. 2 is a graph comparing the ratio of Tyr-Pro-type 5-7 peptides, other Tyr-type peptides, and other lengths of Tyr-Pro-type peptides to the time that the positive drug diazepam affects the sleep time of pentobarbital sodium-induced mice.
FIG. 3 is a graph showing the effect of different casein enzyme products in examples 9-10 and comparative example 3 on the sleep time of pentobarbital sodium-induced mice.
FIG. 4 is a mass spectrum identification BPC-MS of the different casein enzymatic hydrolysis products of examples 9-10 and comparative example 3.
FIGS. 5a to 5c are mass spectrometric identification diagrams of Tyr-Pro-type 5-7 peptides (SEQ. ID. NO.4 to 6) in examples 9 to 10 and in different casein enzymatic products of comparative example 3.
Detailed Description
Specific implementations of the invention are further described below with reference to the drawings and examples, but the implementation and protection of the invention are not limited thereto. It should be noted that the following processes, if not specifically described in detail, can be realized or understood by those skilled in the art with reference to the prior art. The reagents or apparatus used were not manufacturer-specific and were considered conventional products commercially available.
The experimental indexes and the method thereof related to the embodiment of the invention are as follows:
(1) Administration and treatment of mice
192 Kunming mice (6-8 weeks old) were placed in a controlled environment (25+ -2 ℃,12/12h light/dark cycle) and were free of diet. 144 of these were stressed for 2 weeks by randomized chronic stress (including tail clamping, restriction, water deprivation, fasted, inclined cage, diurnal inversion, wet cage, etc.), randomized group (n=12) normal group (normal mice, no stress stimulation), model group (stress stimulation but no drug administration), casein peptide group (each group was orally administered with 1.8mg/kg of gavage casein peptide while stress stimulation) and casein enzymatic products (each group was orally administered with 75mg/kg of gavage casein enzymatic product while stress stimulation). The casein peptide group mice were orally gavaged for 7 days while pressure stimulated, i.e., model group and casein peptide/hydrolysate group co-stimulated for 21 days. After the last lavage, sleep behaviours were determined.
(2) Sodium pentobarbital-induced mouse sleep behavioural assay
The detection is carried out by referring to a tenth chapter of a detection method for improving sleep function in the technical specification of health food detection and evaluation. Mice were started with sodium pentobarbital (42 mg/kg, intraperitoneal injection) 30 minutes after the last oral administration. The number of mice that fell asleep after the disappearance of the regular reflection of the inversion within 15 minutes was then recorded. Sleep latency and sleep duration were recorded in mice over 2 hours with a stopwatch.
(3) Mass spectrum identification method
The bioactive peptide is identified by using ultra-high performance liquid chromatography and mass spectrometry (UPLC-MS/MS), gradient elution chromatography separation is adopted, and the bioactive peptide is identified and quantified by using secondary mass spectrometry, wherein the elution speed is 0.2mL/min, and the sample injection amount is 2 mu L. Mobile phase a was 0.1% formic acid water, B acetonitrile (chromatographic purity), elution procedure: 0-10 min, 22-47% B, 10-12 min, 47-90% B, 12-14 min,90% B, 14-15 min,90% B and (3) balancing the material in the range of percent to 5 percent of B for 15 to 18 minutes to an initial state. The mass spectrum parameters are that the energy of an electron bombardment ion source is 7eV, the capillary voltage is 4500V, the ion source temperature is 200 ℃, the drying gas flow is 8.0L/min, the atomizer pressure is 1.5bar, and the mass scanning range is m/z 50-1500.
Example 1
Pentapeptide Tyr-Pro-Ser-Tyr-Gly, when the gastric lavage amount is 1.8mg/kg, sodium pentobarbital induces the sleeping time of mice to be 2526.28 +/-220.32 s.
Example 2
Pentapeptide Tyr-Pro-Ser-Gly-Ala, when the gastric lavage amount is 1.8mg/kg, sodium pentobarbital induces the sleeping time of the mice to be 3433+/-613.69 s.
Example 3
Pentapeptide Tyr-Pro-Phe-Pro-Gly, and sodium pentobarbital induces mice to sleep for 3055.25 +/-428.78 s when the gastric lavage amount is 1.8 mg/kg.
Example 4
Pentapeptide Tyr-Pro-Glu-Leu-Phe, sodium pentobarbital induces mice to sleep for 3326.14 +/-323.47 s when the gastric lavage amount is 1.8 mg/kg.
Example 5
Heptapeptide Tyr-Pro-Ser-Gly-Ala-Trp-Tyr, sodium pentobarbital induces mice to sleep for 3219.38 +/-658.62 s when the gastric lavage amount is 1.8 mg/kg.
Example 6
Heptapeptide Tyr-Pro-Ser-Tyr-Gly-Leu-Asn, and sodium pentobarbital induces mice to sleep for 3251.38 +/-878.04 s when the gastric lavage amount is 1.8 mg/kg.
Comparative example 1
Hexapeptide Tyr-Phe-Tyr-Pro-Glu-Leu, sodium pentobarbital, when the gastric lavage amount is 1.8mg/kg, induces mice to sleep for 2024.0554 +/-672.99 s.
Comparative example 2
Pentapeptide Tyr-Tyr-Val-Pro-Leu, sodium pentobarbital induced mice sleep time is 1012.0277 + -72.13 s when the gastric lavage amount is 1.8 mg/kg.
Therefore, the Tyr-Pro-type prolonged pentobarbital sodium induces the mice to sleep for a longer time.
Example 7
Dipeptide Tyr-Pro, when the gastric lavage amount is 1.8mg/kg, sodium pentobarbital induces mice to sleep for 1792.69 +/-259.75 s.
Example 8
Tripeptide Tyr-Pro-Ser, when the gastric lavage amount is 1.8mg/kg, sodium pentobarbital induces mice to sleep for 1846.29 +/-398.16 s.
Therefore, the Tyr-Pro-type casein peptide can effectively improve the sleep time, and more preferable 5-7 peptides can obviously prolong the sleep time of the mice induced by sodium pentobarbital.
Example 9
(1) Respectively weighing and adding buffalo milk casein and distilled water according to the mass ratio of 1:10, moderately stirring and dissolving to prepare casein dispersion liquid, and regulating the pH value of a reaction system to 8.0 by using 4M NaOH solution;
(2) Adding trypsin with the mass percentage of 0.5% and mixed protease M (calculated by casein amount) with the mass percentage of 1.5% into the reaction system of the step (1), carrying out enzymolysis for 8 hours at 55 ℃ and inactivating enzyme for 15 minutes at 100 ℃, and cooling, wherein the mixed protease M comprises aminopeptidase and carboxypeptidase (the mass ratio is 3:1);
(3) Centrifuging at 10000rpm and 4 ℃ for 10min, and taking supernatant as casein small molecule peptide solution containing SEQ ID No. 5-7 peptide fragments.
Example 10
(1) Respectively weighing and adding buffalo milk casein and distilled water according to the mass ratio of 1:10, moderately stirring and dissolving to prepare casein dispersion liquid, and regulating the pH value of a reaction system to 6.0 by using 4M NaOH solution;
(2) Adding 0.1% of chymotrypsin and 0.1% of mixed proteinase M (calculated by casein) into the reaction system in the step (1), performing enzymolysis for 1h at 35 ℃, inactivating enzyme at 90 ℃ for 30min, and cooling;
(3) Centrifuging at 8000rpm and 4 ℃ for 20min, and taking supernatant as casein small molecule peptide solution containing SEQ ID No. 5-7 peptide fragments.
Comparative example 3
(1) Respectively weighing and adding buffalo milk casein and distilled water according to the mass ratio of 1:10, moderately stirring and dissolving to prepare casein dispersion liquid, and regulating the pH value of a reaction system to 7.0 by using 4M NaOH solution;
(2) Adding trypsin (calculated by casein amount) with the mass percentage of 0.2% into the reaction system of the step (1), carrying out enzymolysis for 8 hours at 55 ℃, inactivating enzyme for 15 minutes at 100 ℃, and cooling;
(3) Centrifuging at 10000rpm and 4 ℃ for 10min, and taking supernatant as casein small molecule peptide solution.
FIGS. 5a to 5c are mass spectrometric identification diagrams of Tyr-Pro-type 5 to 7 peptides (SEQ. ID. NO.5 to 7) in examples 9 to 10 and in different casein enzymatic products of comparative example 3.
As can be seen from fig. 1, the sleep time of the mice (model group) stimulated by chronic stress was drastically shortened to 735.80 ± 172.83s only by pentobarbital sodium, while the sleep time of the mice stimulated by chronic stress was remarkably prolonged to 2526.28 ±220.32s to 3539.65± 835.41s by pentobarbital sodium after oral administration of the peptide of the Tyr-Pro-type 5-7. And after being treated by dipeptide Tyr-Pro, tripeptide Tyr-Pro-Ser, hexapeptide Tyr-Phe-Tyr-Pro-Glu-Leu and pentapeptide Tyr-Tyr-Val-Pro-Leu, the sleeping time is only 1012.0277 +/-72.13 s-2024.0554+/-672.99 s. The casein Tyr-Pro-type 5-7 peptide can effectively prolong the sleep time of the pentobarbital sodium-induced mice, and has the potential of improving sleep.
As can be seen from fig. 2, comparing the sleep time of the oral gavage sample group with that of the positive drug group, the sleep improvement effect can be more intuitively compared. The result shows that the sleep improvement effect of the casein Tyr-Pro-type 5-7 peptide can reach 57.57% -78.24% of that of a positive control group, the sleep improvement effects of Tyr-Pro and Tyr-Pro-Ser are 40.86% and 42.08% of that of the positive control group, and the sleep improvement effects of the pentapeptides and hexapeptides of the comparative example are only 23.06% and 46.13%.
As can be seen from fig. 3, the sleep time of the mice (model group) induced by pentobarbital sodium was drastically shortened to 735.80 ± 172.83s, while the sleep time of the mice induced by pentobarbital sodium was significantly prolonged to 1745.52 ± 435.3s and 1965.93 ± 558.13s after oral administration of the casein enzymatic products of examples 9 and 10. And after the treatment of comparative example 3, the sleep time was 1312.06.+ -. 427.06s only. The casein enzymolysis product containing Tyr-Pro-type 5-7 peptide can effectively prolong the sleep time of the pentobarbital sodium-induced mice, and has the potential of improving sleep.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.

Claims (10)

1. The application of Tyr-Pro-type casein peptide with sleep improving activity is characterized in that the application is the application in preparing functional food or medicine for improving anxiety-type sleep disorder, and the sequence of the Tyr-Pro-type casein peptide with sleep improving activity is any one of Tyr-Pro,Tyr-Pro-Phe-Pro-Gly(SEQ.ID.NO.1),Tyr-Pro-Glu-Leu-Phe(SEQ.ID.NO.2),Tyr-Pro-Ser-Tyr-Gly-Leu-Asn(SEQ.ID.NO.3),,Tyr-Pro-Ser-Gly-Ala(SEQ.ID.NO.4),Tyr-Pro-Ser-Tyr-Gly(SEQ.ID.NO.5),Tyr-Pro-Ser-Gly-Ala-Trp-Tyr(SEQ.ID.NO.6),Tyr-Pro-Ser.
2. The use according to claim 1, wherein the functional food is a powder granule, a functional beverage, a tabletted candy, a gel soft candy or an oral liquid, and the medicament is a powder, a tablet, a liquid or a capsule.
3. The use according to claim 1, wherein said functional food or medicament further comprises an active ingredient having sleep improving effect and/or acceptable auxiliary materials other than said Tyr-Pro-type casein peptide.
4. The use according to claim 3, wherein the acceptable auxiliary materials in the functional food are milk powder, semen Ziziphi Spinosae, gamma-aminobutyric acid, lactalbumin peptide, collagen peptide, soybean peptide or melatonin, and the acceptable auxiliary materials in the medicine are sustained release agent, excipient, filler, adhesive, wetting agent, disintegrating agent, absorption promoter, adsorption carrier, surfactant or lubricant.
5. The use according to claim 1, characterized in that the Tyr-Pro-type casein peptide with sleep improving activity is a Tyr-Pro-based casein peptide with a C-terminal extension of 5-7 amino acids, seq id No. 4-6.
6. A series of Tyr-Pro-type casein peptides with sleep improving activity, characterized in that the amino acid sequence of the Tyr-Pro-type casein peptides with sleep improving activity is Tyr-Pro-Ser-Gly-Ala(SEQ.ID.NO.4),Tyr-Pro-Ser-Tyr-Gly(SEQ.ID.NO.5),Tyr-Pro-Ser-Gly-Ala-Trp-Tyr(SEQ.ID.NO.6),Tyr-Pro-Ser.
7. A process for preparing a Tyr-Pro-type casein peptide having sleep improving activity as defined in claim 6, comprising the steps of:
(1) Adding casein and water, stirring and dissolving, and adjusting the pH to 6-8 to prepare casein dispersion;
(2) Adding serine proteinase and mixed proteinase M into the casein dispersion liquid in the step (1), carrying out synergistic enzymolysis, inactivating enzyme, and cooling;
(3) Centrifuging at 8000-10000 rpm and 4-10 ℃ for 10-20 min, and taking supernatant to obtain casein small molecule peptide solution containing SEQ ID No. 4-6 peptide fragments.
8. The method for preparing Tyr-Pro-type casein peptide with sleep improving activity according to claim 7, wherein in the step (2), serine proteinase is one of chymotrypsin and trypsin, the mixed proteinase M specifically comprises aminopeptidase and carboxypeptidase, the temperature of the synergistic enzymolysis is 35-55 ℃, and the time of the synergistic enzymolysis is 1-8h.
9. The preparation method of the Tyr-Pro-type casein peptide with the sleep improving activity, which is characterized by comprising the steps of (2) adding 0.2% -2.0% of total protease of serine protease and mixed protease M, wherein the mass ratio of the serine protease to the mixed protease M is (1-10): 10-19, and (2) heating enzymolysis liquid to 90-100 ℃ and boiling for 15-30 min.
10. The application of the casein enzymolysis product prepared by the preparation method of claim 7, namely the casein small-molecule peptide solution containing SEQ ID No. 4-6 peptide fragments in preparing drugs and health care products for improving sleep, wherein the casein enzymolysis product can prolong the sleep time by more than 2.37 times.
CN202411386363.3A 2024-09-30 2024-09-30 Tyr-Pro-type casein peptide with sleep-improving activity and preparation method and application thereof Pending CN119192324A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411386363.3A CN119192324A (en) 2024-09-30 2024-09-30 Tyr-Pro-type casein peptide with sleep-improving activity and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202411386363.3A CN119192324A (en) 2024-09-30 2024-09-30 Tyr-Pro-type casein peptide with sleep-improving activity and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN119192324A true CN119192324A (en) 2024-12-27

Family

ID=94070195

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202411386363.3A Pending CN119192324A (en) 2024-09-30 2024-09-30 Tyr-Pro-type casein peptide with sleep-improving activity and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN119192324A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822851A (en) * 2003-05-15 2006-08-23 塔夫茨大学信托人 Stable analogs of peptide and polypeptide drugs
US20110312892A1 (en) * 2008-06-06 2011-12-22 Federique Balandras Anxiolytic compositions containing alpha s1-casein-derived peptides
JP2016149989A (en) * 2015-02-18 2016-08-22 不二製油株式会社 Food additive composition for preventing or improving sleep disorder
CN115304664A (en) * 2022-06-28 2022-11-08 华南理工大学 Casein peptide with sleep improving effect and preparation method and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822851A (en) * 2003-05-15 2006-08-23 塔夫茨大学信托人 Stable analogs of peptide and polypeptide drugs
US20110312892A1 (en) * 2008-06-06 2011-12-22 Federique Balandras Anxiolytic compositions containing alpha s1-casein-derived peptides
JP2016149989A (en) * 2015-02-18 2016-08-22 不二製油株式会社 Food additive composition for preventing or improving sleep disorder
CN115304664A (en) * 2022-06-28 2022-11-08 华南理工大学 Casein peptide with sleep improving effect and preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IVANO DE NONI: "Review of the potential health impact of β-casomorphins and related peptides", 《EFSA JOURNAL》, vol. 7, no. 2, 31 December 2009 (2009-12-31), pages 1 - 107 *
T TAIRA: "Effect of Beta-Casomorphin on Neonatal Sleep in Rats", 《PEPTIDES》, vol. 11, no. 1, 31 December 1990 (1990-12-31), pages 1 - 4, XP025440374, DOI: 10.1016/0196-9781(90)90101-A *

Similar Documents

Publication Publication Date Title
Ling et al. Preparation and identification of novel inhibitory angiotensin-I-converting enzyme peptides from tilapia skin gelatin hydrolysates: Inhibition kinetics and molecular docking
Wu et al. Purification of angiotensin I-converting enzyme-inhibitory peptides from the enzymatic hydrolysate of defatted canola meal
CN115304664B (en) Casein peptide with sleep-improving effect and preparation method and application thereof
EGGENA et al. The validity of comparing the measurements of angiotensin I generated in human plasma by radioimmunoassay and bioassay
JPS6245207B2 (en)
WO2018021471A1 (en) Food composition for improving brain function
CN114106096A (en) A kind of hexapeptide with improving sleep activity and its application
RU2219925C2 (en) Amino acid compositions and their application in immunodepression
JP2024150778A (en) Hair growth agent and food and drink containing the same
JPH09511747A (en) Pharmaceutical composition for treating cedar pollen allergy
Yu et al. Anxiolytic effects of ACE inhibitory peptides on the behavior of rats in an elevated plus-maze
JP2007534621A (en) Agonist peptides of receptors for ZOT and zonulin
CN119192324A (en) Tyr-Pro-type casein peptide with sleep-improving activity and preparation method and application thereof
ES2606954B1 (en) PROCEDURE FOR OBTAINING A HYDROLYZED CHICKEN FOOT CLAWS WITH ANTI-HANDLING ACTIVITY, HYDROLYZED OBTAINED AND PEPTIDES CONTAINED
Nakagomi et al. Properties and human origin of two angiotensin-I-converting enzyme inhibitory peptides isolated from a tryptic hydrolysate of human serum albumin
EP3419994B1 (en) Peptide inhibitors of calcium channels
CN109200273A (en) A kind of polypeptide is used to prepare the purposes of prevention or treatment fatty liver drug
JP7545479B2 (en) Compositions containing peptides, methods for producing same, and uses of peptides
JPH03503403A (en) biologically active molecules
RU2131438C1 (en) Linear or cyclic oligopeptides showing affinity to opiate receptors, pharmaceutical composition
CN112074529B (en) Peptides, compositions and methods for treating, preventing or ameliorating mood disorders
CN107058269A (en) Medicinal kininogenase and its preparation method and application
CN103288918B (en) Small peptide with dual inhibitory activity against renin and ACE, and applications thereof
D’Hondt et al. Quality analysis of salmon calcitonin in a polymeric bioadhesive pharmaceutical formulation: Sample preparation optimization by DOE
WO2021015041A1 (en) Retardant for progression of aging, and food or beverage containing same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination